It has been reported that knocking down NF-κB in EGFR-mutant lung cancer cells enhanced erlotinib sensitivity, while patient response to erlotinib was associated with high expression of the NF-κB inhibitor IκBα [106], raising hope that a combinatorial treatment targeting both EGFR and NF-κB can have beneficial responses in the clinic. This evidence concerns the gene NFKB1 and lung carcinoma.